Business
aTyr Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting
SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of
About this update from Atyr Pharma, Inc.
[{"type":"text","content":"SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present two posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which is being held virtually April 10 – 15 and May 17 – 21. Details of the poster presentations are as follows: Title: The Neuropilin-2 targeting antibody ATYR2810 inhibits non-small cell lung cancer tumor growth in monotherapy and combination therapyAuthors: Alison G. Barber, Zhiwen Xu, Justin Rahman, Hira Lal Goel, Arthur M. Mercurio, Christoph Burkart, Leslie A. Nangle. aTyr Pharma, San Diego, CA, UMass Medical School, Boston, MA.Abstract Number: 5247Session Category: Tumor BiologySession Title: Human-in-Mouse Models of Human CancerPoster Number: LB234Permanent Abstract Number: LB234Date and Time: April 10 – 15 and May 17 – 21 (9:00AM – 6:00PM ET) Title: A domain-specific antibody to NRP2 down-regulated epithelial-mesenchymal transition genes and enhanced efficacy of standard-of-care therapeutics for aggressive breast cancerAuthors: Zhiwen Xu, Christoph Burkart, Hira Lal Goel, Justin Rahman, Clara Polizzi, Matt Seikkula, Luke Burman, Arthur M. Mercurio, Leslie A. Nangle. aTyr Pharma, San Diego, CA, UMass Medical School, Boston, MA.Abstract Number: 5316Session Category: Experimental and Molecular Therapeutics Session Title: Biological Therapeutic AgentsPoster Number: LB095Permanent Abstract Number: LB095Date and Time: April 10 – 15 and May 17 – 21 (9:00AM – 6:00PM ET) About NRP2 Neuropilin-2 (NRP2) is a cell surface receptor that plays a key role in lymphatic development and in regulating inflammatory responses. In many forms of cancer, high NRP2 expression is associated with worse outcomes. NRP2 can interact with multiple ligands and co-receptors through distinct domains to influence their functional roles, making it a potential drug target with multiple distinct therapeutic applications. NRP2 interacts with type 3 semaphorins and plexins to impact inflammation and with forms of vascular endothelial growth factor (VEGF) and their receptors, to impact lymphangiogenesis. In addition, NRP2 modulates interactions between CCL21 and CCR7 potentially impacting homing of dendritic cells to lymp...